In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. Despite being available for decades, the pharmacological understanding of polymyxin B remains very limited and is a major hindrance to the optimal
No takes yet. Share an insight, caveat, or question.
Tam et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: